Literature DB >> 34592704

Test-retest reliability and cross-cultural applicability of DSM-5 adopted diagnostic criteria for ketamine use disorders.

Nicole D Fitzgerald1, Catherine W Striley2, Joseph J Palamar3, Jan Copeland4, Steven Kurtz5, Linda B Cottler2.   

Abstract

BACKGROUND: Despite increasing prevalence of nonmedical ketamine use globally, data on ketamine use disorders, which are classified in the DSM-5 under criteria for phencyclidine, are limited. This study assessed the reliability and applicability of DSM-based diagnostic criteria for ketamine use disorder.
METHODS: Participants who used ecstasy were recruited through the Tri-City Study of Club Drug Use, Abuse, and Dependence in St. Louis, Miami, and Sydney. Those who reported using ketamine (lifetime use >5 times) were included in these analyses (n = 205). Participants were interviewed using the computerized Substance Abuse Module for Club Drugs (CD-SAM) at baseline and 7 days later for the reliability of diagnoses and individual diagnostic criteria.
RESULTS: Overall, 29.3% met DSM-5 adopted criteria for ketamine use disorder at Time 1. Moderate to excellent test-retest reliability was observed consistently across study sites for any ketamine use disorder (κ = 0.57, Y = 0.61) and severe ketamine use disorder (κ = 0.62, Y = 0.79). Continued use of ketamine despite knowledge of physical or psychological problems was the most frequently endorsed individual criterion (59.0%), followed by reported withdrawal (30.2%) and physically hazardous use (29.8%). All individual criteria had acceptable reliability estimates (κ ≥ 0.41).
CONCLUSIONS: Diagnoses of ketamine use disorder can be reliably evaluated using this fully structured diagnostic instrument's questions and algorithm. Ketamine-related withdrawal among people who use ketamine should be re-evaluated. Considering that after-effects of this dissociative anesthetic can last for many hours, it is important to explore a different timeframe for possible withdrawal effects.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DSM-5; Epidemiology; Ketamine; Nosology; Reliability; Test-retest

Mesh:

Substances:

Year:  2021        PMID: 34592704      PMCID: PMC8678918          DOI: 10.1016/j.drugalcdep.2021.109056

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  46 in total

1.  Inter-observer reliability of DSM-5 substance use disorders.

Authors:  Cécile M Denis; Joel Gelernter; Amy B Hart; Henry R Kranzler
Journal:  Drug Alcohol Depend       Date:  2015-05-27       Impact factor: 4.492

2.  Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria.

Authors:  Linda B. Cottler; Sharon B. Womack; Wilson M. Compton; Arbi Ben-Abdallah
Journal:  Hum Psychopharmacol       Date:  2001-12       Impact factor: 1.672

3.  The reliability of the CIDI-SAM: a comprehensive substance abuse interview.

Authors:  L B Cottler; L N Robins; J E Helzer
Journal:  Br J Addict       Date:  1989-07

4.  A re-analysis of the reliability of psychiatric diagnosis.

Authors:  R L Spitzer; J L Fleiss
Journal:  Br J Psychiatry       Date:  1974-10       Impact factor: 9.319

5.  A proposed solution to the base rate problem in the kappa statistic.

Authors:  E L Spitznagel; J E Helzer
Journal:  Arch Gen Psychiatry       Date:  1985-07

6.  Ketamine applications beyond anesthesia - A literature review.

Authors:  Agata Nowacka; Malgorzata Borczyk
Journal:  Eur J Pharmacol       Date:  2019-07-23       Impact factor: 4.432

7.  Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.

Authors:  Ella J Daly; Jaskaran B Singh; Maggie Fedgchin; Kimberly Cooper; Pilar Lim; Richard C Shelton; Michael E Thase; Andrew Winokur; Luc Van Nueten; Husseini Manji; Wayne C Drevets
Journal:  JAMA Psychiatry       Date:  2018-02-01       Impact factor: 21.596

8.  Comparing assessments of DSM-IV substance dependence disorders using CIDI-SAM and SCAN.

Authors:  W M Compton; L B Cottler; K B Dorsey; E L Spitznagel; D E Mager
Journal:  Drug Alcohol Depend       Date:  1996-07       Impact factor: 4.492

9.  Cognitive impairment in chronic ketamine abusers.

Authors:  Chenxi Zhang; Yan Xu; Bin Zhang; Wei Hao; Wai Kwong Tang
Journal:  Psychiatry Res       Date:  2020-06-08       Impact factor: 3.222

Review 10.  Increased use of ketamine for the treatment of depression: Benefits and concerns.

Authors:  Kyoung-Sae Na; Yong-Ku Kim
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-08-07       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.